

# Yuan He

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/104041/publications.pdf>

Version: 2024-02-01

14  
papers

285  
citations

1040056

9  
h-index

1125743

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

555  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 724-734.	6.1	9
2	The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity. <i>Cancers</i> , 2022, 14, 299.	3.7	11
3	A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/ $\beta^2$ -catenin signaling pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 30.	8.6	23
4	Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1 $\alpha$ mediated XPC transcription. <i>Oncogene</i> , 2020, 39, 6893-6905.	5.9	30
5	CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 1663-1671.	3.4	28
6	Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis. <i>Nature Communications</i> , 2019, 10, 533.	12.8	26
7	Development of Bispecific Antibody Derivatives for Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2019, 1884, 335-347.	0.9	5
8	CD20-selective inhibition of CD47-SIRP $\alpha$ signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. <i>Oncolmmunology</i> , 2018, 7, e1386361.	4.6	58
9	A novel recombinant human Frizzled-7 protein exhibits anti-tumor activity against triple negative breast cancer via abating Wnt/ $\beta^2$ -catenin pathway. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 103, 45-55.	2.8	21
10	CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 2852-2852.	1.4	0
11	A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members. <i>Scientific Reports</i> , 2017, 7, 13301.	3.3	6
12	Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5. <i>Journal of Investigative Dermatology</i> , 2016, 136, 541-544.	0.7	18
13	Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. <i>Oncolmmunology</i> , 2016, 5, e1202390.	4.6	35
14	A CD47 blocking TRAIL fusion protein with dual pro-phagocytic and pro-apoptotic anticancer activity. <i>British Journal of Haematology</i> , 2014, 164, 304-307.	2.5	15